Certolizumab

Summary

Certolizumab (CHEMBL4297565) is a phase-3 clinical-stage antibody; indicated across 3 conditions including rheumatoid arthritis and lung neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297565
Name	Certolizumab
Type	Antibody
Max phase	3

Also known as: Certolizumab, CERTOLIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
lung neoplasm	2	MONDO:0021117	MONDO:0008903
lung adenocarcinoma	1	MONDO:0005061	EFO:0000571

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
Not specified	5
PHASE4	3
PHASE2	3
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT01602302	PHASE4	TERMINATED	Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis
NCT02132234	PHASE4	UNKNOWN	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
NCT03414502	PHASE3	RECRUITING	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT04991025	PHASE2	RECRUITING	Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
NCT07138898	PHASE2	NOT_YET_RECRUITING	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT06028438	PHASE2	COMPLETED	A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
NCT02120807	PHASE1	COMPLETED	Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
NCT04725422	Not specified	RECRUITING	CHronic Nonbacterial Osteomyelitis International Registry
NCT01098201	Not specified	COMPLETED	Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)
NCT01582568	Not specified	TERMINATED	EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn’s Disease With CERTOLIZUMAB Treatment
NCT02714881	Not specified	COMPLETED	Lipids, Inflammation, and CV Risk in RA
NCT03955861	Not specified	COMPLETED	Ultrasound Enthesitis Response in Psoriatic Arthritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).